Clinical Trials Logo

Clinical Trial Summary

Cognitive deficits (CD) are considered one of the essential characteristics in psychotic disorders and occur throughout the course of the disease, being a key characteristic in the evolution of the disease and in the functionality and prognosis of patients. Intervening in the early stages of the disease and specifically in adolescence, a period of high brain plasticity can reduce disabilities in adulthood associated with early-onset psychosis. The objective of this study is to assess the efficacy of cognitive rehabilitation therapy in adolescents with a first psychotic episode, comparing two groups of these patients: a first group (CCRT) will carry out 40 sessions of a computerized cognitive remediation therapy with the usual treatment too, and a second group will perform only the usual treatment (TAU). The main hypothesis is that the CCRT group will present a significant improvement in verbal memory, visual attention, executive function, and social cognition and will present better global functioning compared to the TAU group.


Clinical Trial Description

Cognitive deficits (DC) are considered one of the essential features in psychotic disorders and occur throughout the course of the disease. Recent meta-analyses have shown that cognitive remediation therapy can reduce DCs in basic cognitive processes such as attention, memory, and problem solving and can have an impact on social functioning. The aim of this study is to evaluate the effectiveness of a computerized cognitive remediation intervention in cognitive and functional improvement in patients with a first psychotic episode that is psychopathologically stable but presents cognitive impairment. The hypotheses that are raised are: 1. In relation to the cognitive field. Participants in the computerized cognitive remediation therapy + treatment as usual (CCRT) group versus the participants in the treatment as usual (TAU) group are expected to improve in (evaluated by MATRICS): 1. Verbal memory 2. Visual attention 3. Executive function 4. Social cognition 2. In relation to other symptoms. Participants in the CCRT group versus the participants in the TAU group are expected to: 1. Present better Global Functioning evaluated through C-GAS. Parallel groups will be compared with patients between 12 and 18 years of age diagnosed with schizophrenia / schizoaffective recruited at the Hospital Sant Joan de Déu Barcelona. A total of 50 randomly distributed patients will be included (n = 25 CCRT; n = 25 TAU). CCRT group will perform a total of 40 computerized cognitive remediation (cCR) sessions through the NeuroPersonalTrainer program in addition to the treatment as usual, and TAU group will perform only the treatment as usual. An evaluation will be performed before the start of treatment, a second evaluation after the end of the 40cCRsessions/ TAU, and a third evaluation (follow-up) 6 months after the end of the 40cCRsessions. Data Management The aforementioned variables will be collected on the one hand in paper format, in a data collection notebook created by ADHOC for the study that will be kept with a key and the data in electronic format, derived from the computerized programs and tests will be stored with a password, all of this under the responsibility of the principal investigator. The monitoring plan consists in that each visit made to carry out the study will be recorded in the participant's clinical history and the variables of clinical or neuropsychological interest will be included in the history and in a way that can be accessed to verify the data. Verification of all the data of each participant will be carried out once the study has been completed by the participant and the data collection has been completed and all the participant's data has been coded. Data that cannot be recovered will be coded as "missing" and participants who could not be tracked as "drop-outs". The data of each participant will be coded and included in a database for later analysis. Data that could lead to the identification of the participant will not be stored in the database. No information of any kind to identify the participants will be included. Only the study doctor and his collaborators will be able to relate the data collected in the study with his medical history. No adverse effects are expected as it is a protocol that does not include drugs or invasive procedures. In the case of detecting an adverse effect, it would be notified and coded in the database. Statistical analysis The group will be randomized as follows: parallel, CCRT Group compared to TAU Group. Randomization will be performed using permuted blocks with a fixed size of 8 patients assigned a 4: 4 ratio according to computerized allocation i is done blindly. Randomization is performed by an outside person to whom the program applies. Following the CONSORT statement for controlled trials (Moher et al. 2010), the intention-to-treat analysis will be used. This consists of the comparison of the CCRT Group, including all patients, as originally assigned after randomization. The analysis of the missing and drop-outs will also be carried out according to the CONSORT statement. An analysis of the descriptive and contingency tables will be carried out. Tests will be carried out to evaluate the normality of the results through the Kolmogorov-Smirnov test. For variables with a normal distribution, Student's t-test will be applied and non-parametric tests (U-Mann Witney) will be applied for results without normal distribution. For the evaluation of the pre-post differences, repeated measures analysis of variance (ANOVA) designed with the CCRT Group versus TAU Group condition will be used as the independent variable and the baseline and post-treatment evaluations as the time points. An analysis of covariance with repeated measures (ANCOVA) will be performed, including potentials as covariates. The effect size for calculating changes in scores will be calculated in 2 complementary groups in two ways. Eta partial squared (h2p) will be used to calculate the effect size of the scores between baseline and post-treatment evaluations. The effect size of the number needed to treat (NNT) will also be calculated since it is a clinically significant measure that indicates the number of people who would need to be treated to achieve a specific therapeutic goal. Furthermore, it will be determined if the cognitive changes are reliable using TAU Group test-re-test reliability coefficients in order to calculate the standard error of measurement according to Medalia (2005). CCRT Group patients whose score changes to a coefficient value of 1.64 or higher (90% CI) will be identified as a reliable improvement. Finally, the use of repeated measures ANOVA will be used to assess changes from baseline to 3-month follow-up in CCRT Group, with baseline and follow-up as time points. Logistic regression models will also be included to study dichotomous variables in the event that the bivariate analysis has been significant. For the statistical analysis, the statistical package STATA 12 will be used. Data codebook Code=RHC_0XX Age=Date of birth Sex=Sex N_Sessions=Sessions performed Peduc=paternal education level Meduc=maternal education level Poccup=paternal occupation Moccup=maternal occupation residence=place of residence kindh=kind of house Npobl=nº hab poblacion Npersh=number of persons at home SES=socioeconomic status F_Psq_history=Family Psyquiatric History OSC=Obstetric Risk perinatal=perinatal history psychomot=psychomotor development language=language development read_write=reading and writing development Psq_history= Personal Psychiatric History Psq_age=age first contact mental health service Psq_pharma=history of pharmacological treatment Psq_psychology=history of psychological treatments Psq_1HOSP_age=age of first hospitalization Psq_1HOSP_days=days first hospitalization Medical_history=relevant medical history academic_rep=repetition of academic year course=academic level freq_subs_lifec= maximum frequency of café throughout life freq_subs_3m= frequency of café last 3 months K-SADS-PL-5: Psychopathology PANS-PS_0: Positive symptoms basal PANS-PS_40s: Positive symptoms 40 sessions follow-up PANS-PS_6m: Positive symptoms 6 months follow-up PANS-NS_0: Negative symptoms basal PANS-NS_40s: Negative symptoms 40 sessions follow-up PANS-DS_6m: Negative symptoms 6 months follow-up PANS-DS_0: Disorganization symptoms basal PANS-DS_40s: Disorganization symptoms 40 sessions follow-up PANS-DS_6m: Disorganization symptoms 6 months follow-up GAF_0= Global Functioning basal GAF_40s= Global Functioning 40 sessions follow-up GAF_6m= Global Functioning 6 months follow-up W_V_Pd=Vocabulary direct W_V_T= Vocabulary t-score W_C_Pd= Block Design direct W_C_T= Block Design t-score W_S_Pd= Similarities direct W_S_T= Similarities t-score W_M_Pd=Matrix reasoning direct W_M_T Matrix reasoning t-score W_B_Pd=Figure Weights direct W_B_T=Figure Weights t-score ICV_Pe= Verbal Comprehension ICV_CI= Verbal Comprehension Index IFR_Pe= Fluid Reasoning IFR_CI= Fluid Reasoning Index ICG_Pe= General Ability ICG_CI= General Ability Index W_DT_Pd_0= working memory Digit span direct W_DT_T_0= working memory Digit span t-score W_Dd_Pd_0= working memory direct Digit span direct W_Dd_Pd_0= working memory direct Digit span t-score W_Di_Pd_0= working memory indirect Digit span direct W_Di_Pd_0= working memory indirect Digit span t-score W_CN_Pd_0= Processing Speed coding direct W_CN_Pd_0= Processing Speed coding t-score W_LN_Pd_0= working memory Letter-number sequencing direct W_LN_T_0= working memory Letter-number sequencing t-score W_DT_Pd_40s= working memory Digit span direct 40 sessions follow-up W_DT_T_40s = working memory Digit span t-score 40 sessions follow-up W_Dd_Pd_40s = working memory direct Digit span direct 40 sessions follow-up W_Dd_Pd_40s = working memory direct Digit span t-score 40 sessions follow-up W_Di_Pd_40s = working memory indirect Digit span direct 40 sessions follow-up W_Di_Pd_40s = working memory indirect Digit span t-score 40 sessions follow-up W_CN_Pd_40s = Processing Speed coding direct 40 sessions follow-up W_CN_Pd_40s = Processing Speed coding t-score 40 sessions follow-up W_LN_Pd_40s = working memory Letter-number sequencing direct 40 sessions follow-up W_LN_T_40s = working memory Letter-number sequencing t-score 40 sessions follow-up W_DT_Pd_6m= working memory Digit span direct 6 months follow-up W_DT_T_6m= working memory Digit span t-score 6 months follow-up W_Dd_Pd_6m= working memory direct Digit span direct 6 months follow-up W_Dd_Pd_6m= working memory direct Digit span t-score 6 months follow-up W_Di_Pd_6m= working memory indirect Digit span direct 6 months follow-up W_Di_Pd_6m= working memory indirect Digit span t-score 6 months follow-up W_CN_Pd_6m= Processing Speed coding direct 6 months follow-up W_CN_Pd_6m= Processing Speed coding span t-score 6 months follow-up W_LN_Pd_6m= working memory Letter-number sequencing direct 6 months follow-up W_LN_T_6m= working memory Letter-number sequencing t-score 6 months follow-up CPT_CI_0=Attention basal CPT_CI_40s=Attention 40 sessions follow-up CPT_CI_RP=Attention 6 months follow-up CPT_O_0= Attention, omissions basal CPT_O_40s =Attention, omissions 40 sessions follow-up CPT_O_RP=Attention, omissions 6 months follow-up CPT_C_0= Attention, commissions basal CPT_C_40s =Attention, commissions 40 sessions follow-up CPT_C_RP=Attention, commissions 6 months follow-up CPT_HRT_0= Attention, reaction time basal CPT_HRT_40s =Attention, reaction time 40 sessions follow-up CPT_HRT_RP=Attention, reaction time 6 months follow-up CPT_D_0= Attention, detectability basal CPT_D_40s =Attention, detectability 40 sessions follow-up CPT_D_RP=Attention, detectability 6 months follow-up CPT_V_0= Attention, variability basal CPT_V_40s =Attention, variability 40 sessions follow-up CPT_V_RP=Attention, variability 6 months follow-up TMT-A_Pd_0=Processing Speed TMT-A, direct score basal TMT-A_Pd_40s=Processing Speed TMT-A, direct score 40 sessions follow-up TMT-A_Pd_RP=Processing Speed TMT-A, direct score , 6 months follow-up TMT-A_T_0=Processing Speed TMT-A, t-score basal TMT-A_T_40s=Processing Speed TMT-A, t-score, 40 sessions follow-up TMT-A_T_6m=Processing Speed TMT-A, t-score, 6 months follow-up TMT-B_Pd_0=executive functions TMT-B, direct score basal TMT-B_Pd_40s=executive functions TMT-B, direct score 40 sessions follow-up TMT-B_Pd_RP=executive functions TMT-B, direct score , 6 months follow-up TMT-B_T_0=executive functions TMT-B, t-score basal TMT-B_T_40s=executive functions TMT-B, t-score, 40 sessions follow-up TMT-B_T_6m=executive functions TMT-B, t-score, 6 months follow-up HVLT_Pd_0=Long term Verbal Memory, direct, basal HVLT_Pd_40s =Long term Verbal Memory, direct, 40 sessions follow-up HVLT_Pd_6m =Long term Verbal Memory, direct, 6 months follow-up HVLT_T_0=Long term Verbal Memory, t-score basal HVLT_T_40s =Long term Verbal Memory t-score 40 sessions follow-up HVLT_T_6m =Long term Verbal Memory t-score 6 months follow-up HVLT_Pd_0=Verbal Memory Learning, direct, basal HVLT_Pd_40s =Verbal Memory Learning, direct, 40 sessions follow-up HVLT_Pd_6m =Verbal Memory Learning, direct, 6 months follow-up HVLT_T_0=Verbal Memory Learning, t-score basal HVLT_T_40s =Verbal Memory Learning, t-score 40 sessions follow-up HVLT_T_6m =Verbal Memory Learning, t-score 6 months follow-up Rey_CQ_0= Copy Quality Visual Memory basal Rey_CQ_40s = Copy Quality Visual Memory 40 sessions follow-up Rey_CQ_6m = Copy Quality Visual Memory 6 months follow-up Rey _CA_0= Copy Accuracy Visual Memory basal Rey_CA_40s = Copy Accuracy Visual Memory 40 sessions follow-up Rey_CA_6m = Copy Accuracy Visual Memory 6 months follow-up Rey _MQ_0= Memory Quality Visual Memory basal Rey_MQ_40s =Memory Quality Visual Memory 40 sessions follow-up Rey_MQ_6m =Memory Quality Visual Memory 6 months follow-up Rey_MA_0= Memory Accuracy Visual Memory basal Rey_MA_40s =Memory Accuracy Visual Memory 40 sessions follow-up Rey_MA_6m =Memory Accuracy Visual Memory 6 months follow-up WSCT_E_0= executive functions, WSCT total errors basal WSCT_E_40s = executive functions, WSCT total errors 40 sessions follow-up WSCT_E_6m = executive functions, WSCT total errors 6 months follow-up WSCT_PE_0= executive functions, WSCT percentage errors basal WSCT_PE_40s = executive functions, WSCT percentage errors totals 40 sessions follow-up WSCT_PE_6m = executive functions, WSCT percentage errors totals 6 months follow-up WSCT_persev_0= executive functions, WSCT persevering responses basal WSCT_persev_40s = executive functions, WSCT persevering responses 40 sessions follow-up WSCT_persev_6m = executive functions, WSCT persevering responses 6 months follow-up WSCT_Epersev_0= executive functions, WSCT persevering errors basal WSCT_Epersev_40s = executive functions, WSCT persevering errors 40 sessions follow-up WSCT_Epersev_6m = executive functions, WSCT persevering errors 6 months follow-up WSCT_PEpersev_0= executive functions, WSCT percentage persevering errors basal WSCT_PEpersev_40s = executive functions, WSCT percentage persevering errors 40 sessions follow-up WSCT_PEpersev_6m = executive functions, WSCT percentage persevering errors 6 months follow-up WSCT_ENopersev_0= executive functions, WSCT non-persevering errors basal WSCT_ENopersev_40s = executive functions, WSCT non-persevering errors 40 sessions follow-up WSCT_ENopersev_6m = executive functions, WSCT non-persevering errors 6 months follow-up WSCT_PENopersev_0= executive functions, WSCT percentage non-persevering errors basal WSCT_PENopersev_40s = executive functions, WSCT percentage non-persevering errors 40 sessions follow-up WSCT_PENopersev_6m= executive functions, WSCT percentage non-persevering errors 6 months follow-up WSCT_categories_0= executive functions, WSCT categories basal WSCT_categories_40s = executive functions, WSCT categories non-persevering errors 40 sessions follow-up WSCT_categories_6m= executive functions, WSCT categories 6 months follow-up FAS_Pd_0=Processing Speed FAS Word Fluency, direct scores basal FAS_Pd_40s=Processing Speed FAS Word Fluency, direct scores 40 sessions follow-up FAS_T_6m=Processing Speed FAS Word Fluency, direct scores 6 months follow-up FAS_T_0=Processing Speed FAS Word Fluency, t-scores basal FAS_T_40s=Processing Speed FAS Word Fluency, t-scores40 sessions follow-up FAS_T_6m=Processing Speed FAS Word Fluency, t-scores 6 months follow-up Semantic_Pd_0=Processing Speed Semantic Word Fluency, direct scores basal Semantic_Pd_40s=Processing Speed Semantic Word Fluency, direct scores 40 sessions follow-up Semantic _Pd_6m=Processing Speed Semantic Word Fluency, direct scores 6 months follow-up Semantic _T_0=Processing Speed Semantic Word Fluency, t-scores basal Semantic _T_40s=Processing Speed Semantic Word Fluency, t-scores 40 sessions follow-up Semantic _T_6m=Processing Speed Semantic Word Fluency, t-scores 6 months follow-up FACES_Pd_0= Social Cognition basal FACES_Pd_40s= Social Cognition 40 sessions follow-up FACES_Pd_6m= Social Cognition 6 months follow-up ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05405946
Study type Interventional
Source Fundació Sant Joan de Déu
Contact Ester Camprodon Rosanas, Psychology
Phone . +34 677056074
Email ester.camprodon@sjd.es
Status Recruiting
Phase N/A
Start date March 19, 2019
Completion date March 2023

See also
  Status Clinical Trial Phase
Completed NCT05321602 - Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder Phase 1
Terminated NCT03230097 - This Study Tests Whether BI 409306 Prevents Patients With a Specific Type of Mental Illness (Attenuated Psychosis Syndrome) From Becoming Worse. This Study Looks at How Well Patients Tolerate the Medicine and How Effective it is Over 1 Year Phase 2
Completed NCT03497663 - VIA Family - Family Based Early Intervention Versus Treatment as Usual N/A
Active, not recruiting NCT05726617 - Avatar Intervention for the Treatment of Cannabis Use Disorder in Patients With Severe Mental Health Disorders N/A
Not yet recruiting NCT03807388 - ReMindCare App for Patients From First Episode of Psychosis Unit. N/A
Recruiting NCT02874573 - Tocilizumab in Schizophrenia Phase 1
Terminated NCT02584114 - Brain Effects of Memory Training in Early Psychosis N/A
Completed NCT02906553 - The Role of Nitric Oxide in Cognition in Schizophrenia N/A
Terminated NCT02841956 - Reducing Duration of Untreated Psychosis Through Rapid Identification and Engagement N/A
Completed NCT01981356 - Acceptance and Commitment Therapy for the Inpatient Treatment of Psychosis Phase 0
Withdrawn NCT02213887 - Study of the Effects of Pantoprazole on Levels of Prescribed Psychiatric Medications Phase 4
Recruiting NCT02009969 - Serial Comparisons of Abdominal and Neurological MRI Scans N/A
Recruiting NCT02848469 - Irish Omega-3 Study Phase 2
Completed NCT02648321 - Motivational Intervention for Physical Activity in Psychosis N/A
Enrolling by invitation NCT00762866 - Psychiatric Genotype/Phenotype Project Repository
Completed NCT00484302 - Specialized Addiction Treatment Versus Treatment as Usual for Young Patients With Cannabis Abuse and Psychosis N/A
Completed NCT00844922 - Safety of Org 34517 900 mg in Patients Who Received Org 34517 in a Previous Trial (Study 28133/P05842) Phase 2
Completed NCT00130923 - Risperidone Long-acting Versus Oral Risperidone in Patients With Schizophrenia and Alcohol Use Disorder Phase 4
Completed NCT00455234 - Rapid Tranquillization Trial: TREC-India II Phase 3
Completed NCT00128479 - A United States Study of the Safety and Tolerability of Corlux for Psychotic Symptoms in Psychotic Major Depression Phase 3